Board of Directors

Dr. Malgorzata Szerszeniewska

President / Chief Executive Officer

Szerszeniewska is a co-founder of EastHORN. Previously, she was president of AbCRO, Inc., an American-owned CRO operating in Europe. Prior to that Dr. Szerszeniewska spent more than 10 years at Covance, where she held various positions including Regional Resource Manager, Project Manager, Director of Strategic Development and Clinical Operations in Europe, and was responsible for development of the company’s Clinical Development Services in the European region.

Before joining the CRO industry, she worked as an Anesthesiology and Intensive Care Specialist at Warsaw University Hospital. Dr. Szerszeniewska’s therapeutic experience includes oncology, neurology, cardiovascular, psychiatry and gastrointestinal medicine. Dr. Szerszeniewska received her Medical Diploma from the Warsaw Medical University.

malgorzata.szerszeniewska@easthorn.eu

After working for more than 25 years in the clinical trials industry, I still could not find a European CRO that fully utilized all the advantages that Europe offers in terms of patient enrollment and data quality. In starting EastHORN, I made it my personal mission to become more than just an average research partner, to develop into a company that is the go-to source for exceptional clinical trials in Europe. We are planning to achieve our goal through inviting exceptional people from the industry to join us and to share our values and philosophy. Advocating for a unique personal approach and devotion towards our clients’ needs, we commit ourselves to excellence in clinical trials.

Dr. Alan Wood

Non Executive Director

Dr. Wood is one of the co-founders of EastHORN. Now retired from executive management, he serves as a non-executive director on the board of EastHORN. Dr. Wood had a 40-year career in clinical development, first in “big pharma” in Switzerland, then with European and Asia-Pacific management responsibilities in two major global CROs. Before starting EastHORN with Dr. Szerszeniewska, he was Senior Director, R&D Operations at a French biotechnology company.

Dr. Wood graduated in pharmacy and pharmacology from the University of Otago, New Zealand.

alan.wood@easthorn.eu

When we started EastHORN we focussed our activities in Central and Eastern Europe because that is where we are based, and this region is well-recognized as a location for high-quality clinical research.
Demand from our clients has encouraged us to expand to other countries in Western Europe with similar advantages: access to patients and high-quality investigator sites.
As we grow and expand our geographic reach we are determined to keep the characteristics of a small company: responsive, nimble, easy to work with, senior management involvement in operations and a commitment to the highest professional standards.

Iain Gordon

Vice President / Chief Business Officer

Iain joined EastHORN in 2013 to play a key role in the next stages of EastHORN’s ambitious plans for growth. He has been managing CRO business development in Europe and North America for more than 15 years. Since the first tentative steps into Poland and Hungary in the 90’s he has enjoyed and been a key part of the spectacular growth in clinical services in this region and beyond. Senior management roles as European Head and Global VP of Business Development have enabled Iain to be at the leading edge of business and corporate development within the global CRO industry.

Iain is based in the UK and graduated in Cell Biology from the University of Glasgow.
iain.gordon@easthorn.eu

Since joining the CRO industry in the 90’s I have been continually impressed with the quality and speed of clinical work in Europe. In an industry where timelines are absolutely key, but deadlines are often missed, I have lost count of the times that European operations and sites have saved the day. As this region matures it now offers the best of both worlds combining experience and dynamic enrolment, continually outperforming some of the more exotic and less predictable regions that have started to offer clinical services more recently.